The 90% confidence interval ranges for MET (1.01-1.21) and BUP and norBUP (1.03-1.69) were within respective no-effect ranges (0.7-1.43 and 0.5-2.0). Opioid pharmacodynamic scores were similar with and without MET/BUP with no symptoms
of withdrawal/overdose; no new safety signal for FTR when combined with a stable opioid regimen. 15 .5% in East and Southern Africa). 3 The oral opioid analgesics methadone (MET) and buprenorphine (BUP) are commonly prescribed as maintenance treatment for opioid dependence. [4] [5] [6] MET is a chiral compound normally administered as racemic mixture of R-and S-enantiomers, with R-MET as the pharmacologically active enantiomer. 7, 8 For maintenance treatment, BUP is usually administered as a sublingual coformulation with the opioid receptor antagonist naloxone (NLX), which has poor oral bioavailability, to prevent parenteral abuse. 9 Plasma concentrations of both MET and BUP have a linear relationship with dose, although BUP exposure is not directly dose proportional. 10, 11 Both MET and BUP/NLX must be clinically titrated to achieve a stable maintenance state for each individual without symptoms of either opioid withdrawal or overdose, and thus, evaluation of potential drug-drug interactions is important. 12 Fostemsavir (FTR) is a highly soluble methyl phosphate prodrug of the membrane-permeable but poorly soluble ARV temsavir (TMR), currently under clinical development for treatment-experienced individuals with limited further treatment options. FTR is metabolized by alkaline phosphatase at the luminal surface of the small intestine to yield active TMR a first-in-class, potent HIV-1 attachment inhibitor. 13, 14 Presystemic conversion to TMR is supported by the lack of quantifiable FTR observed in blood after FTR administration. 15 TMR binds to the HIV gp120 envelope protein and blocks its subsequent attachment to target cell CD4 receptors 16 independent of the coreceptor tropism of the virion. 13, [16] [17] [18] [19] In vitro data show broad HIV-1 isolate susceptibility to TMR, except for subtype AE and, possibly, group O. 17, 18 TMR also has a unique resistance profile with no in vitro cross-resistance to other ARV classes. 16, 17 TMR has a plasma half-life of approximately 11 hours, shows limited accumulation (<2-fold) with twice-daily (BID) dosing of FTR, and steady-state TMR exposure is 2-3 days. Food effects on TMR PK are fat-and calorie-dependent, with time to maximum plasma concentration (Tmax) increased from 2 hours fasted to 4 hours with a standard meal and 6.5 hours with a high-fat meal, and an 81% increase in the area under the TMR concentration-time curve noted with a high-fat meal but not with a standard meal. Based on these observations and Phase III clinical data, FTR is considered suitable for administration with or without food. 15, 20 FTR is administered as an extended-release (ER) tablet formulation following data from a regional absorption study
Conclusions
showing an improved PK profile compared with an earlier immediaterelease formulation. 14 Clinical data from the Phase III BRIGHTE study (NCT02362503) of FTR 600 mg ER BID, given to heavily treatmentexperienced adults with HIV-1 infection susceptible to 1 or 2 active ARV classes, showed a 0.8 log 10 copies/mL decline in HIV-1 RNA during 8 days of functional FTR monotherapy (vs a 0.2 log 10 copies/mL decline on placebo; P < 0.0001), 21 and a 54% rate of HIV virological
What is already known about this subject
• Regional human immunodeficiency virus (HIV) prevalence rates are high in people who inject drugs, including those on maintenance opioids.
• Fostemsavir is being evaluated in heavily treatmentexperienced HIV-1-infected adults.
• As HIV-1-infected adults receiving methadone or buprenorphine for opioid addiction may be prescribed fostemsavir, it is important to identify potential drugdrug interactions.
What this study adds
• Methadone and buprenorphine can be administered with fostemsavir without dose adjustments, which is supported by the similar opiate withdrawal and overdose scale scores between methadone or buprenorphine alone and in combination with fostemsavir.
• Coadministration of fostemsavir and maintenance opioids was generally well tolerated.
suppression among those receiving FTR with an optimized background therapy for 24 and 48 weeks. were to be administered during the study unless prescribed for treatment of specific clinical events. 
| Study design and treatments

| Study objectives
The primary objectives of the study were to assess the effect of mul- (COWS), 33 Subjective Opiate Withdrawal Scale (SOWS), 34 Objective
Opiate Withdrawal Scale (OOWS) 34 and Opiate Overdose Assessment (OOA) 35 ; and the short-term safety and tolerability.
| PK sampling and analytical methods
Serial blood samples for PK analysis were collected predose and at 0. The PD impact of FTR on the withdrawal and overdose effect of MET or BUP/NLX using COWS, SOWS, OOWS and OOA questionnaires was determined using descriptive statistical summary for the total score of each questionnaire.
| Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMA-COLOGY, 36 and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18. however, given TMR PK parameters were comparable with other study results and that 2 separate cohorts of participants were in the MET and BUP parts of the study by design, it would be difficult to associate any differences to MET or BUP.
| Effect of FTR on BUP and norBUP
Coadministration of FTR 600 mg ER BID with MET or BUP/NLX was well tolerated and produced no new safety signal, including no clinically meaningful impact on trends of opiate withdrawal or overdose effect.
It is likely that heavily treatment-experienced, HIV-1-infected adults may need to take complicated ARV regimens, which include inhibitors and/or inducers of drug metabolism and/or transporters.
The complex DDI effects caused by ARV regimens may require a titration of a pre-existing maintenance opioid, which could impact a stable maintenance state without symptoms of either opioid withdrawal or overdose. Additionally, patient adherence to a medication they associate with opiate withdrawal symptoms is likely to be low. approval of the version to be published and each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content. All authors have agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
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